Poolbeg Pharma advances POLB 001 into UK trial - ICYMI

Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF) CEO, Jeremy Skillington, talked with Proactive about recent progress alongside Principal Scientist Liam Tremble, highlighting key regulatory and commercial developments for POLB 001. Tremble explained that the company has secured full regulatory approval from the MHRA, alongside HRA and ARSAC clearances, marking a major milestone that allows the POLB 001 clinical trial to proceed in the UK.